CL2017002960A1 - Compuesto para la profilaxis o el tratamiento de daño al órgano - Google Patents

Compuesto para la profilaxis o el tratamiento de daño al órgano

Info

Publication number
CL2017002960A1
CL2017002960A1 CL2017002960A CL2017002960A CL2017002960A1 CL 2017002960 A1 CL2017002960 A1 CL 2017002960A1 CL 2017002960 A CL2017002960 A CL 2017002960A CL 2017002960 A CL2017002960 A CL 2017002960A CL 2017002960 A1 CL2017002960 A1 CL 2017002960A1
Authority
CL
Chile
Prior art keywords
treatment
damage
compound
prophylaxis
organ damage
Prior art date
Application number
CL2017002960A
Other languages
English (en)
Inventor
Der Graaf Adrianus Cornelis Van
Robert Henk Henning
Leo Edwin Deelman
Gerrit Jan Willem Euverink
Original Assignee
Sulfateq Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56014996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017002960(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sulfateq Bv filed Critical Sulfateq Bv
Publication of CL2017002960A1 publication Critical patent/CL2017002960A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS PARA LA PROFILAXIS O EL TRATAMIENTO DEL DAÑO AL ÓRGANO MEDIANTE LA RESTAURACIÓN DE LA FUNCIÓN ENDOTELIAL Y/O LA INHIBICIÓN DE LA PRODUCCIÓN DE ESPECIES DE OXÍGENO REACTIVAS Y ESPECIALMENTE A COMPUESTOS PARA LA PROFILAXIS O EL TRATAMIENTO DEL DAÑO RENAL DIABÉTICO. ESPECÍFICAMENTE, LA INVENCIÓN PRESENTE RELACIONA A 6- HIDROXI-2,5,7,8-TETRAMETILCROMAN-2-IL) (PIPERAZIN-1-IL) METANONA O N, 6-DIHIDROXI-2,5,7,8-TETRAMETILCROMAN-2-CARBOXAMIDA O UNA SAL O BASE FARMACÉUTICAMENTE ACEPTABLE DE LOS MISMOS PARA EL USO EN LA PROFILAXIS O TRATAMIENTO DEL DAÑO AL ÓRGANO MEDIANTE LA RESTAURACIÓN DE LA FUNCIÓN ENDOTELIAL O LA INHIBICIÓN DE LA PRODUCCIÓN DE ESPECIES REACTIVAS DE OXÍGENO Y DAÑO ORGÁNICO A LOS RIÑONES DIABÉTICOS.</p>
CL2017002960A 2015-05-22 2017-11-21 Compuesto para la profilaxis o el tratamiento de daño al órgano CL2017002960A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2014843 2015-05-22

Publications (1)

Publication Number Publication Date
CL2017002960A1 true CL2017002960A1 (es) 2018-03-16

Family

ID=56014996

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002960A CL2017002960A1 (es) 2015-05-22 2017-11-21 Compuesto para la profilaxis o el tratamiento de daño al órgano

Country Status (15)

Country Link
US (2) US10676452B2 (es)
EP (1) EP3297625B1 (es)
JP (2) JP6967456B2 (es)
CN (1) CN107660148B (es)
AU (1) AU2016268975B2 (es)
BR (1) BR112017024854B1 (es)
CA (1) CA2986300C (es)
CL (1) CL2017002960A1 (es)
DK (1) DK3297625T3 (es)
ES (1) ES2927699T3 (es)
HU (1) HUE060167T2 (es)
MX (1) MX2017014912A (es)
PL (1) PL3297625T3 (es)
PT (1) PT3297625T (es)
WO (1) WO2016188766A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2010010C2 (en) * 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
US10676452B2 (en) * 2015-05-22 2020-06-09 Sulfateq B.V. Compound for the prophylaxis or treatment of organ damage
EP3672592A1 (en) 2017-08-25 2020-07-01 Sulfateq B.V. 6-chromanol derivatives for use as a medicament
EP3672593A1 (en) 2017-08-25 2020-07-01 Sulfateq B.V. Medicaments for the treatment of vasoconstriction related diseases or disorders
CA3079483A1 (en) 2017-11-22 2019-05-31 Khondrion Ip B.V. Compounds as mpges-1 inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681890A (en) 1984-10-30 1987-07-21 Kuraray Co., Ltd. 3,4-dihydrobenzopyran compounds and pharmaceutical composition containing the same
CA1286299C (en) 1985-05-13 1991-07-16 Johji Yamahara 3,4-dihydrobenzopyran derivatives and medicinal uses thereof
CA1338012C (en) 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
US5266709A (en) 1989-03-13 1993-11-30 Ono Pharmaceutical Co., Ltd. Benzopyran derivatives
US5506245A (en) * 1992-10-12 1996-04-09 Adir Et Compagnie Thiazolidinedione compounds
US5457109A (en) 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
FR2756284B1 (fr) 1996-11-26 2000-04-28 Adir Nouveaux derives du benzopyrane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6335445B1 (en) 1997-03-24 2002-01-01 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
EP0894089B9 (en) 1997-05-02 2003-04-02 Dr. Reddy's Laboratories Ltd. Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
AR019190A1 (es) * 1998-07-08 2001-12-26 Sod Conseils Rech Applic Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos
US6768008B2 (en) 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
AU2003221281A1 (en) 2003-02-26 2004-09-17 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Benzopyran compounds, process for preparing the same and their use
JP4377881B2 (ja) * 2003-08-01 2009-12-02 日本曹達株式会社 フェニルアゾール化合物、製造法および抗酸化薬
WO2005033092A1 (en) * 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
CA2878567C (en) * 2012-07-12 2021-02-23 Khondrion Ip B.V. Chromanyl derivatives for treating mitochondrial disease
NL2010010C2 (en) * 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
US10676452B2 (en) * 2015-05-22 2020-06-09 Sulfateq B.V. Compound for the prophylaxis or treatment of organ damage

Also Published As

Publication number Publication date
CA2986300C (en) 2024-02-20
HUE060167T2 (hu) 2023-02-28
JP2018520106A (ja) 2018-07-26
AU2016268975B2 (en) 2021-08-12
MX2017014912A (es) 2018-06-13
AU2016268975A1 (en) 2017-11-30
CN107660148B (zh) 2021-03-09
US10676452B2 (en) 2020-06-09
US20210024485A1 (en) 2021-01-28
CN107660148A (zh) 2018-02-02
PT3297625T (pt) 2022-09-27
ES2927699T3 (es) 2022-11-10
WO2016188766A1 (en) 2016-12-01
BR112017024854A2 (pt) 2018-08-14
JP2021120381A (ja) 2021-08-19
US20180170892A1 (en) 2018-06-21
DK3297625T3 (da) 2022-10-17
EP3297625A1 (en) 2018-03-28
CA2986300A1 (en) 2016-12-01
BR112017024854B1 (pt) 2023-12-26
JP6967456B2 (ja) 2021-11-17
PL3297625T3 (pl) 2022-11-14
EP3297625B1 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
CL2017002960A1 (es) Compuesto para la profilaxis o el tratamiento de daño al órgano
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
DOP2019000201A (es) Compuestos inhibidores del vih
CO2018013293A2 (es) Derivados de pirazolopirimidina como inhibidor de quinasa
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
CO2020004301A2 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih
CR20150416A (es) Inhibidores de cdc7
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
AR103680A1 (es) Inhibidores selectivos de bace1
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
CL2017001209A1 (es) Inhibidor de cinasa aurora a
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
CR20160016A (es) Pirazolpiridinas sustituidas
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MD3395821T2 (ro) Compuși antitumorali
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
CL2020002139A1 (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado.
CO2019005165A2 (es) Compuesto de piridona como inhibidor de c-met
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
SV2016005310A (es) Derivados de diheterociclo enlazado a cicloalquilo
AR109328A1 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana